Day: February 20, 2024

Event to feature KOL perspective on emerging MASH therapies SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET. To register, click here. During...

CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 26, 2024 at 1:30 p.m. ET in New York City. Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.   Tonix Pharmaceuticals Holding Corp.* Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio...

VANCOUVER, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced C$1,000,000 non-brokered private placement (the “Offering”) by issuing 11,028,429 units (the “Units”) at a price of C$0.05 per Unit, for gross proceeds of C$551,421. Each Unit consists of one Sonoro common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one additional Sonoro common share for a period of three years from the closing of the private placement at an exercise price of C$0.07 per share. The net proceeds from the Offering will be used to fund the ongoing development of the Company’s Cerro Caliche gold project in Sonora, Mexico. All...

LOS ANGELES, Feb. 20, 2024 (GLOBE NEWSWIRE) — via IBN — Nextech3D.ai (CSE: NTAR) (OTCQX: NEXCF) (FSE: 1SS), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls, Miele and others including major e-commerce platform integrations with Shopify, BigCommerce and WooCommerce, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Nextech3D.ai’s recent announcement of the launch of the next era of GPT AI 3D product solutions leveraging proprietary algorithms. To hear the audio production, visit: https://www.nnw.fm/VFivh To read the original press release, visit: https://nnw.fm/H4iQF The initiative...

Value-based care program offers Las Vegas patients access to high quality cancer care while reducing costs for employers SAN FRANCISCO and LAS VEGAS, Feb. 20, 2024 (GLOBE NEWSWIRE) — Today, The Oncology Institute (TOI), one of the largest value-based oncology practices in the country, announced its partnership with Carrum Health. This collaboration aims to provide high-quality, cost-effective breast cancer care to patients in TOI’s Las Vegas, Nevada market, with plans for further expansion into additional markets in the coming year. Through employers, Carrum Health will offer patients a comprehensive bundled package for breast cancer care, covering two years treatment, including chemotherapy, office visits, and symptom management through TOI. The partnership will focus on patients with non-metastatic breast cancer patients in Las...

WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr. The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety. MNPR-101-Zr is a zirconium-89 (imaging radioisotope) labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly selective against the urokinase plasminogen activator receptor (uPAR). PET imaging...

VANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) — Finning International Inc. (TSX: FTT) (“Finning” or the “Company” or “we”, “our” or “us”) today announced that Christopher Patterson, a member of the company’s Board of Directors (Board), has decided to step down from the Board for personal reasons, effective February 16, 2024. “Chris has been a valuable member of the Board and we have appreciated his experience and thoughtful insights over the course of his 14-year tenure,” said Harold Kvisle, chair of Finning’s Board of Directors. Mr. Kvisle added, “On behalf of the Board, I would like to thank Chris for his service and longstanding commitment to Finning, and we wish him all the best in the future.” About FinningFinning International is the world’s largest Caterpillar dealer delivering unrivalled service to customers...

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), a media and consumer products company with expertise in livestream shopping and social commerce, announced their participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek. Xcel Brands CEO, Robert D’Loren, sat down with Noble Capital Markets Senior Research, Michael Kupinski, for this exclusive two-part series. Topics covered include:Part one, Xcel Brands CEO Robert D’Loren provides a corporate overview, discussing Xcel’s core business model, their brands, key revenue figures, current financial outlook, and their new e-commerce platform, ORME. Learn more on Xcel Brands here. Part two highlights the launch of ORME, a next generation short form video marketplace, which will become a game changer in the social influencer...